Research Topics
| Robert WelliverSummaryAffiliation: State University of New York at Buffalo Country: USA Publications
| Collaborators
|
Detail Information
Publications
The immune response to respiratory syncytial virus infection: friend or foe?Robert C Welliver
Department of Pediatrics, School of Medicine and Biomedical Sciences, The State University of New York at Buffalo, Buffalo, NY, USA
Clin Rev Allergy Immunol 34:163-73. 2008..Thus, recovery from primary (and perhaps later) RSV infection is dependent on the quality of innate immune responses. These findings should have enormous significance to the development of vaccines and antiviral compounds...- Innate immune responses in respiratory syncytial virus infectionsSubramaniam Krishnan
Graduate Program in Microbiology and Immunology, Arizona Respiratory Center, University of Arizona HSC, Tucson, Arizona, USA
Viral Immunol 17:220-33. 2004.... 
Effects of early environment on mucosal immunologic homeostasis, subsequent immune responses and disease outcomePearay L Ogra
Department of Pediatrics, Division of Infectious Diseases, University at Buffalo, State University of New York, School of Medicine, and Women and Children s Hospital of Buffalo, Buffalo, NY 14222, USA
Nestle Nutr Workshop Ser Pediatr Program 61:145-81. 2008....
Does the viral subtype influence the biennial cycle of respiratory syncytial virus?Gordana Mlinaric-Galinovic
Department of Virology, Croatian National Institute of Public Health and University Medical School of Zagreb, Zagreb, Croatia
Virol J 6:133. 2009..In order to determine if these differences are accounted for by the circulation of different RSV subtypes, we studied the prevalence of RSV subtype A and B strains in Zagreb County from 1 January 2006 to 31 December 2007...- The biennial cycle of respiratory syncytial virus outbreaks in CroatiaGordana Mlinaric-Galinovic
Department of Virology, Croatian National Institute of Public Health, Rockefellerova 12, 10000 Zagreb, Croatia
Virol J 5:18. 2008..Knowledge of this biennial pattern should be useful in predicting the onset of RSV outbreaks in Croatia, and would facilitate planning for the prevention and control of RSV infections in the region... - Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy childrenRobert C Welliver
School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Women and Children s Hospital, Buffalo, NY 14222, USA
Curr Med Res Opin 26:2175-81. 2010..To review the fatalities among children hospitalized with respiratory syncytial virus (RSV) infection, and identify factors leading to a fatal outcome... - Temperature, humidity, and ultraviolet B radiation predict community respiratory syncytial virus activityRobert C Welliver
Division of Infectious Diseases, State University of New York at Buffalo and Women and Children s Hospital, Buffalo, NY 14222, USA
Pediatr Infect Dis J 26:S29-35. 2007.... - Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responsesTimothy P Welliver
MedImmune, Inc, Gaithersburg, MD, USA
J Infect Dis 195:1126-36. 2007..It is widely believed that both viral replication and inappropriately enhanced immune responses contribute to disease severity. In infants, RSV LRTI is known to be more severe than influenza virus LRTI... - Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infectionRobert C Welliver
Department of Pediatrics, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, and the Division of Infectious Diseases, Children s Hospital of Buffalo, New York 14222, USA
J Pediatr 143:S112-7. 2003..Pulmonary hypertension and cyanosis are associated with worse outcomes in infants with congenital heart disease, and prolonged viral replication accounts for more severe illness in immunocompromised individuals... - The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virusRobert Welliver
State University of New York at Buffalo and Women and Children s Hospital of Buffalo, New York, USA
Paediatr Respir Rev 10:6-8. 2009..Accurate information on when to institute and withdraw prophylactic therapy against RSV will depend on local epidemiological data... - Pharmacotherapy of respiratory syncytial virus infectionRobert C Welliver
Department of Pediatrics, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Women and Children s Hospital of Buffalo, Buffalo, New York, United States
Curr Opin Pharmacol 10:289-93. 2010.... - Respiratory syncytial virus and other respiratory virusesRobert C Welliver
State University of New York and Children s Hospital of Buffalo, 219 Bryant Street, Buffalo, NY 14222, USA
Pediatr Infect Dis J 22:S6-10; discussion S10-2. 2003..Preliminary evidence suggests that severe RSV and influenza viral infections are mediated via chemokine up-regulation... - Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant casesTimothy P Welliver
MedImmune, Inc, Gaithersburg, MD, USA
Pediatr Infect Dis J 27:S92-6. 2008..Severe infantile RSV and influenza virus LRTI is characterized by inadequate (rather than excessive) adaptive immune responses, robust viral replication and apoptotic crisis... - Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in the respiratory tracts of human infants following paramyxovirus infectionMatthew B Elliott
Wyeth Research, Pearl River, NY 10965, USA
J Med Virol 79:447-56. 2007..Taken together, the data suggested that paramyxovirus infection perturbs MMP-9/TIMP-1 homeostasis that in turn may contribute to the severity of respiratory tract disease... - Production of interferon gamma in respiratory syncytial virus infection of humans is not associated with interleukins 12 and 18Roberto P Garofalo
Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA
J Med Virol 73:289-94. 2004..Immune responses characterized by relatively greater release of IL18 may be associated with milder forms of bronchiolitis... - Respiratory syncytial virus infection: therapy and preventionRobert C Welliver
Department of Pediatrics, State University of New York at Buffalo and Children's Hospital of Buffalo, NY 14222, USA
Paediatr Respir Rev 5:S127-33. 2004 - Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonatesSubramaniam Krishnan
Graduate Program in Microbiology and Immunology, University of Arizona Health Sciences Center, Tucson, USA
J Infect Dis 188:433-9. 2003..Thus, exposure to RSV does not appear to occur before birth, and adaptive immune insufficiency or greater innate responses may account for early life RSV-induced illnesses... - Zileuton reduces respiratory illness and lung inflammation, during respiratory syncytial virus infection, in miceR Charles Welliver
Department of Pediatrics, Division of Infectious Diseases, State University of New York at Buffalo, and Children s Hospital, Buffalo, New York 14222, USA
J Infect Dis 187:1773-9. 2003..Leukotrienes appear to contribute substantially to the pathogenesis of RSV-related disease... - A comparison of epidemiologic and immunologic features of bronchiolitis caused by influenza virus and respiratory syncytial virusRoberto P Garofalo
Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA
J Med Virol 75:282-9. 2005.... - The compound DATEM inhibits respiratory syncytial virus fusion activity with epithelial cellsShinpei Ohki
Department of Physiology and Biophysics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14214, USA
Antiviral Res 58:115-24. 2003..DATEM may prove to be effective in limiting the infectivity of RSV by interference with the fusion of the viral envelope with target cell membranes... - Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infectionRobert C Welliver
Department of Pediatrics, State University of New York at Buffalo, Children's Hospital of Buffalo, USA
Pediatr Infect Dis J 21:457-61. 2002